These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868 [TBL] [Abstract][Full Text] [Related]
6. A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in Healthy Volunteers. Osborn M; Stachulski N; Sun H; Blais J; Venishetty V; Raccuglia M; Kankam M; Colvin R; Segal F Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061156 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Das S; Johnson A; McEntee L; Farrington N; Kirby A; Unsworth J; Jimenez-Valverde A; Kolamunnage-Dona R; Bousquet J; Alibaud L; Sable C; Zalacain M; Everett M; Hope W Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32778549 [No Abstract] [Full Text] [Related]
9. Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model. Melchers MJ; van Mil AC; Lagarde C; den Hartigh J; Mouton JW Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630197 [TBL] [Abstract][Full Text] [Related]
10. Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. Reck F; Bermingham A; Blais J; Capka V; Cariaga T; Casarez A; Colvin R; Dean CR; Fekete A; Gong W; Growcott E; Guo H; Jones AK; Li C; Li F; Lin X; Lindvall M; Lopez S; McKenney D; Metzger L; Moser HE; Prathapam R; Rasper D; Rudewicz P; Sethuraman V; Shen X; Shaul J; Simmons RL; Tashiro K; Tang D; Tjandra M; Turner N; Uehara T; Vitt C; Whitebread S; Yifru A; Zang X; Zhu Q Bioorg Med Chem Lett; 2018 Feb; 28(4):748-755. PubMed ID: 29336873 [TBL] [Abstract][Full Text] [Related]
11. Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing Dean CR; Barkan DT; Bermingham A; Blais J; Casey F; Casarez A; Colvin R; Fuller J; Jones AK; Li C; Lopez S; Metzger LE; Mostafavi M; Prathapam R; Rasper D; Reck F; Ruzin A; Shaul J; Shen X; Simmons RL; Skewes-Cox P; Takeoka KT; Tamrakar P; Uehara T; Wei JR Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061293 [TBL] [Abstract][Full Text] [Related]
12. Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Andes D; Craig WA Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855 [TBL] [Abstract][Full Text] [Related]
14. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829 [TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Wiskirchen DE; Crandon JL; Furtado GH; Williams G; Nicolau DP Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model. Bernhard F; Odedra R; Sordello S; Cardin R; Franzoni S; Charrier C; Belley A; Warn P; Machacek M; Knechtle P Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253212 [TBL] [Abstract][Full Text] [Related]
18. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541 [TBL] [Abstract][Full Text] [Related]
19. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. Bhalodi AA; Crandon JL; Williams G; Nicolau DP Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model. Tashiro S; Hayashi M; Takemura W; Igarashi Y; Liu X; Mizukami Y; Kojima N; Enoki Y; Taguchi K; Yokoyama Y; Nakamura T; Matsumoto K Pharm Res; 2021 Jan; 38(1):27-35. PubMed ID: 33404990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]